Fact CheckerSign in

NCT03915366CompletedPhase 2/3

Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe Pneumonia

Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe Pneumonia: a Multicenter, Open-label Randomized Controlled Clinical Trial

Source: ClinicalTrials.gov · Last updated 19 Sept 2025

Brief summary (registry, in English)

This trial will evaluate whether empirical treatment against cytomegalovirus and tuberculosis improves survival of HIV-infected infants with severe pneumonia.

Status (registry)
Completed
Phase (registry)
Phase 2/3
Study type
Interventional
Enrollment
563 (actual)
First submitted
10 Apr 2019
Start date
1 Mar 2020
Primary completion date
31 Jan 2025
Lead sponsor
Hospital Universitario 12 de Octubre
Diseases
Tuberculosis, HIV
NCT number
NCT03915366
EudraCT number
2019-001749-42

What you commit to

  • Study type: Interventional · Phase 2/3
  • Participants enrolled: 563
  • From 1 Mar 2020 to the primary completion date, 31 Jan 2025
  • 13 sites in 11 countries
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Patient previously treated for TB or currently on treatment for TB
  • Documented evidence of close TB exposure (household contact of a patient with documented TB during the lifetime of the child, or currently receiving TB-T)
  • Systemic immunosuppressive medications. Steroids will be considered to be immunosuppressing only if \>2 mg/kg of prednisone or equivalent during \>15 days

Other illness

  • Active malignancies
  • Evidence of condition other than HIV and pneumonia which precludes, to the judgment of the clinical researcher, enrollment in this trial due to risk for the patient. In case of doubt, the Trial Management Team will be contacted to assess eligibility

Lab values

  • Pure wheezers defined as a clear clinical improvement after a bronchodilator test (give a challenge of rapid-acting inhaled bronchodilator for up to three times 15-20 minutes apart. Count the breaths and look for chest indrawing again, and then re-classify)
  • Hb \<6 g/dL in the screening blood test or in a test done in the last 48 hours. Transfusion is permitted to achieve \>6 g/dL if the patient's state allows it. In case a transfusion is administered, the patient can be enrolled

Other

  • Clinical TB (pulmonary or extrapulmonary) diagnosis, defined as the necessity of TB-T prescribed by a physician, at the moment of randomization
  • Known bacteriologically confirmed TB case (at least one biological specimen positive by culture or Xpert MTB/RIF) at the moment of randomization
  • Less than 2.5 kg of weight
  • Neutropenia \<500 /mm3 in the screening blood test or in a test done in the last 48 hours. Repeating the test is allowed to check eligibility

Who the study is looking for

  • Age 28 days to 365 days of age
  • Pneumonia defined as chest indrawing or fast breathing for age, for infants 28 to 60 days of age ≥60 breaths per minute and for infants 61 to 365 days of age, ≥50 breaths per minute.
  • Current hospitalization due to pneumonia with criteria for parenteral antibiotics (1 or more criteria)
    • Chest indrawing with HIV infection
    • No improvement with oral treatment.
    • One or more danger signs according to WHO 5,44,45
    • Central cyanosis or saturation of O2 \<90%
    • Severe respiratory distress, e.g. grunting or very severe chest indrawing
    • Signs of pneumonia with a general danger sign:
    • Unable to drink or breastfeed
    • Persisting vomiting
    • Convulsions in the last 24 hours
    • Lethargic or unconscious
    • Stridor while calm
    • Severe malnutrition
  • HIV-confirmed infection (with at least one molecular method: DNA polymerase chain reaction (PCR) or RNA PCR/viral load).
  • Informed consent obtained

Age in the registry: 28 days to 365 days · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (13)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Programme PACCI. Centre Hospitalier Cocody.
Coordinator of this site? Confirm its status
AbidjanCôte d’IvoireUnknown status
Fundación para la Investigación Biomédica del Hospital 12 de Octubre
Coordinator of this site? Confirm its status
MadridSpainUnknown status
Université de Bourdeaux
Coordinator of this site? Confirm its status
BourdeauxFranceUnknown status
INSERM
Coordinator of this site? Confirm its status
ToulouseFranceUnknown status
University of Lincoln
Coordinator of this site? Confirm its status
LincolnUnited KingdomUnknown status
PENTA Foundation
Coordinator of this site? Confirm its status
PadovaItalyUnknown status
Malawi Liverpool Welcome Trust. Queen Elizabeth Central Hospital College of Medicine
Coordinator of this site? Confirm its status
BlantyreMalawiUnknown status
Cemtro de Investigaçao em Saúde da Manhiça
Coordinator of this site? Confirm its status
ManhiçaMozambiqueUnknown status
Hospital Central Maputo
Coordinator of this site? Confirm its status
MaputoMozambiqueUnknown status
Stichting Katholieke Universiteit Radboudumc
Coordinator of this site? Confirm its status
NijmegenNetherlandsUnknown status
Makerere University - Mulago Hospital
Coordinator of this site? Confirm its status
KampalaUgandaUnknown status
Lusaka Teaching Hospital
Coordinator of this site? Confirm its status
LusakaZambiaUnknown status
University of Zimbabwe Clinical Research Centre
Coordinator of this site? Confirm its status
HarareZimbabweUnknown status

Related publications

This page is information, not medical advice. Discuss any trial with your doctor.